Novakand Pharma AB (publ) (FRA:3EE0)

Germany flag Germany · Delayed Price · Currency is EUR
0.0001
0.00 (0.00%)
Last updated: Dec 1, 2025, 8:20 AM CET
-99.86%
Market Cap1.96M
Revenue (ttm)n/a
Net Income (ttm)-4.69M
Shares Outn/a
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.0001
Previous Close0.0001
Day's Range0.0001 - 0.0001
52-Week Range0.0001 - 0.1552
Betan/a
RSI44.32
Earnings DateNov 21, 2025

About Novakand Pharma AB

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. The com... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 5
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3EE0
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.